Latest Chrysos (ASX:C79) News

Deal headlines and big drill hits shared the stage with a brutal sell-off in a handful of tiny raisings. The week’s biggest winners were backed by clear news; the biggest losers showed what happens when buyers vanish after a halt.

Small caps stole the spotlight, with a handful of stocks doubling on deal news and early-stage project updates. Large miners were steadier, but even they couldn’t fully escape the week’s sharp gap moves.

Chrysos Corporation Limited reported a robust 1H FY26 with revenue up 49% and EBITDA soaring 152%, driven by expanding adoption of its PhotonAssay technology and strategic global deployments.

CSIRO has sold about half its shares in Chrysos Corporation through a block trade, reducing its stake by roughly 9%, yet remains a committed substantial shareholder with a six-month escrow on its retained shares.

Chrysos Corporation reports nearly one million monthly PhotonAssay samples and reiterates strong FY26 revenue guidance, while unveiling next-gen assay technologies and global expansion plans.

Chrysos Corporation reported record FY25 financial results, driven by strong global demand for its innovative PhotonAssay™ technology. The company expanded its footprint, enhanced sustainability credentials, and strengthened governance, positioning itself for continued growth.

Chrysos Corporation reported robust FY25 results driven by record sample volumes and expanded global deployments of its PhotonAssay technology. The company reiterates strong FY26 guidance amid growing international partnerships.

Chrysos Corporation has confirmed its FY25 financial results, reporting $66.1 million in revenue and $16.1 million EBITDA, while reinforcing its commitment to advancing its PhotonAssay technology for mining analysis.

Chrysos Corporation reported a robust FY25 with 46% revenue growth and an 80% jump in EBITDA, driven by expanding adoption of its PhotonAssay technology and a landmark contract with gold giant Newmont. The company projects further growth in FY26 with revenue guidance of $80-90 million.

Chrysos Corporation reported a robust 46% revenue increase to A$66.1 million for FY25 but faced a significant net loss of A$8.2 million, reflecting rising costs and operational challenges.

Chrysos Corporation reports robust FY25 financial growth driven by global adoption of its PhotonAssay technology and secures a strategic Master Services Agreement with gold giant Newmont. The company projects further revenue and EBITDA expansion in FY26.

Chrysos Corporation reported a strong FY25 with 46% revenue growth and key contracts signed with industry leaders, setting an optimistic tone for FY26.